Cita APA

Tono, Y., Ishihara, M., Miyahara, Y., Tamaru, S., Oda, H., Yamashita, Y., . . . Katayama, N. (2018). Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: A feasibility study with analysis of biomarkers. Oncotarget.

Chicago Style Citation

Tono, Yasutaka, et al. "Pertuzumab, Trastuzumab and Eribulin Mesylate Therapy for Previously Treated Advanced HER2-positive Breast Cancer: A Feasibility Study With Analysis of Biomarkers." Oncotarget 2018.

Cita MLA

Tono, Yasutaka, et al. "Pertuzumab, Trastuzumab and Eribulin Mesylate Therapy for Previously Treated Advanced HER2-positive Breast Cancer: A Feasibility Study With Analysis of Biomarkers." Oncotarget 2018.